Page 3 - Lawrence Eichenfield News Today

This segment of Dr. Eichenfield’s interview featured a discussion about Eichenfield’s response to the FDA’s approval of cantharadin 0.7%, or VP-102, for molluscum contagiosum.

Acne on a baby's face is a common occurrence for many young children. Find out what causes baby acne and how to treat it.

A therapy has reached the pediatric vitiligo market—and more are on the way. Dermatologists Raj Chovatiya, MD, PhD, and Lawrence Eichenfield, MD, review the major shifts in pediatric vitiligo care and pharmacotherapy developments live from the Revolutionizing Atopic Dermatitis 2023 Annual Meeting in Washington, DC.

HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more.

Janus kinase (JAK) and phosphodiesterase-4 (PDE-4) inhibitors were primary topics covered at the third symposium at the Revolutionizing Atopic Dermatitis fifth annual conference.

Eichenfield discussed his first presentation at the Revolutionizing Atopic Dermatitis conference, with his discussion covering systemic atopic dermatitis treatment for infants.

Eichenfield discussed the major takeaways from his Revolutionizing Atopic Dermatology conference presentation regarding recent data on PDE4 and JAK inhibitors for eczema patients.

The Revolutionizing Atopic Dermatitis conference, set to begin on April 29 in Washington, DC, promises to offer symposia on emerging therapies and new insights into treating atopic dermatitis (AD).

A set of highlights from some of the impactful breakthroughs covered in dermatology this past month, including phase 3 trial data bimekizumab, tapinarof, and other treatments.

A recent analysis showed that a combination treatment made of phosphate, adapalene, and benzoyl peroxide known as IDP-126 was well-tolerated and effective in pediatric participants with acne.